Udilović, Ana

Link to this page

http://farfar.pharmacy.bg.ac.rs/APP/faces/author.xhtml?author_id=orcid%3A%3A0000-0002-8208-4628&item_offset=0&project_offset=0&sort_by=dc.date.issued
Authority KeyName Variants
orcid::0000-0002-8208-4628
  • Udilović, Ana (1)
Projects

Author's Bibliography

The impact of treatment choices on potential drug–drug interactions in hypertensive patients

Perić, Aneta; Udilović, Ana; Dobrić, Silva; Vezmar-Kovačević, Sandra

(John Wiley and Sons Inc, 2021) 

TY  - JOUR
AU  - Perić, Aneta
AU  - Udilović, Ana
AU  - Dobrić, Silva
AU  - Vezmar-Kovačević, Sandra
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4017
AB  - Aims: The aim of this study was to analyse potential drug–drug interactions (pDDIs) and their potential adverse drug reactions (ADRs) among hypertensive patients. Moreover, we investigated the possibility of reducing pDDIs with different treatment choices. Methods: This was a cross-sectional study including all outpatients with hypertension and two or more medications, treated in a university hospital in Serbia. Lexicomp Interact (Lexi-Comp, Inc., Hudson, OH) was used for identification of pDDIs and potential ADRs. Treatment choices were explored according to patient characteristics, treatment guidelines and the interacting potential of drugs. Data were analysed using descriptive analysis and multiple logistic regression. Results: A total of 350 patients were included in this study, with average age (77 [36–98] years and 6.1 [2.5]) medications. The majority of patients (86.0%) had at least one clinically significant pDDI, and the average was 3.78 (3.90) (range 1–25). Suggestions for treatment change aimed mainly at eliminating drug duplications, reducing the use of thiazide diuretics, sulfonylureas, alpha-lipoic acid and pentoxifylline and increasing the use of calcium-channel blockers, when appropriate. pDDIs would have decreased to 2.10 (2.52), P <.001, yet male gender, ≥6 medications, cardiovascular diseases, diabetes, benign prostatic hyperplasia, would be predictive of two or more pDDIs. The main potential adverse outcomes of pDDIs were hypotension, renal failure, hypoglycaemia, bradycardia and lactic acidosis. Conclusion: Careful choice of drugs can reduce but not eliminate pDDIs and their potential ADRs in hypertensive patients. Close monitoring for hypotension, renal failure, hypoglycaemia, bradycardia and lactic acidosis is necessary.
PB  - John Wiley and Sons Inc
T2  - British Journal of Clinical Pharmacology
T1  - The impact of treatment choices on potential drug–drug interactions in hypertensive patients
VL  - 88
IS  - 5
SP  - 2340
EP  - 2348
DO  - 10.1111/bcp.15168
ER  - 
@article{
author = "Perić, Aneta and Udilović, Ana and Dobrić, Silva and Vezmar-Kovačević, Sandra",
year = "2021",
abstract = "Aims: The aim of this study was to analyse potential drug–drug interactions (pDDIs) and their potential adverse drug reactions (ADRs) among hypertensive patients. Moreover, we investigated the possibility of reducing pDDIs with different treatment choices. Methods: This was a cross-sectional study including all outpatients with hypertension and two or more medications, treated in a university hospital in Serbia. Lexicomp Interact (Lexi-Comp, Inc., Hudson, OH) was used for identification of pDDIs and potential ADRs. Treatment choices were explored according to patient characteristics, treatment guidelines and the interacting potential of drugs. Data were analysed using descriptive analysis and multiple logistic regression. Results: A total of 350 patients were included in this study, with average age (77 [36–98] years and 6.1 [2.5]) medications. The majority of patients (86.0%) had at least one clinically significant pDDI, and the average was 3.78 (3.90) (range 1–25). Suggestions for treatment change aimed mainly at eliminating drug duplications, reducing the use of thiazide diuretics, sulfonylureas, alpha-lipoic acid and pentoxifylline and increasing the use of calcium-channel blockers, when appropriate. pDDIs would have decreased to 2.10 (2.52), P <.001, yet male gender, ≥6 medications, cardiovascular diseases, diabetes, benign prostatic hyperplasia, would be predictive of two or more pDDIs. The main potential adverse outcomes of pDDIs were hypotension, renal failure, hypoglycaemia, bradycardia and lactic acidosis. Conclusion: Careful choice of drugs can reduce but not eliminate pDDIs and their potential ADRs in hypertensive patients. Close monitoring for hypotension, renal failure, hypoglycaemia, bradycardia and lactic acidosis is necessary.",
publisher = "John Wiley and Sons Inc",
journal = "British Journal of Clinical Pharmacology",
title = "The impact of treatment choices on potential drug–drug interactions in hypertensive patients",
volume = "88",
number = "5",
pages = "2340-2348",
doi = "10.1111/bcp.15168"
}
Perić, A., Udilović, A., Dobrić, S.,& Vezmar-Kovačević, S.. (2021). The impact of treatment choices on potential drug–drug interactions in hypertensive patients. in British Journal of Clinical Pharmacology
John Wiley and Sons Inc., 88(5), 2340-2348.
https://doi.org/10.1111/bcp.15168
Perić A, Udilović A, Dobrić S, Vezmar-Kovačević S. The impact of treatment choices on potential drug–drug interactions in hypertensive patients. in British Journal of Clinical Pharmacology. 2021;88(5):2340-2348.
doi:10.1111/bcp.15168 .
Perić, Aneta, Udilović, Ana, Dobrić, Silva, Vezmar-Kovačević, Sandra, "The impact of treatment choices on potential drug–drug interactions in hypertensive patients" in British Journal of Clinical Pharmacology, 88, no. 5 (2021):2340-2348,
https://doi.org/10.1111/bcp.15168 . .
4